Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause T1D: Paving the Path to Prevention Adult Immunization Center Dermatology Hot Topics

Interstitial lung disease

>

Latest News

© Michael_Vi/stock.adboe.com

Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-ILD Trial in Progressive Pulmonary Fibrosis

By Grace Halsey

February 11th 2025

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.

Editorial Board

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.